133 related articles for article (PubMed ID: 9815553)
41. Low NDRG1 mRNA expression predicts a poor prognosis in neuroblastoma patients.
Matsushita K; Uchida K; Saigusa S; Ide S; Hashimoto K; Koike Y; Otake K; Inoue M; Tanaka K; Kusunoki M
Pediatr Surg Int; 2013 Apr; 29(4):363-8. PubMed ID: 23296375
[TBL] [Abstract][Full Text] [Related]
42. The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.
Domingo-Fernandez R; Watters K; Piskareva O; Stallings RL; Bray I
Pediatr Surg Int; 2013 Feb; 29(2):101-19. PubMed ID: 23274701
[TBL] [Abstract][Full Text] [Related]
43. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.
Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19190-5. PubMed ID: 23091029
[TBL] [Abstract][Full Text] [Related]
44. A novel synthetic naïve human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin.
Villa A; Lovato V; Bujak E; Wulhfard S; Pasche N; Neri D
MAbs; 2011; 3(3):264-72. PubMed ID: 21487243
[TBL] [Abstract][Full Text] [Related]
45. Myc proteins as therapeutic targets.
Gustafson WC; Weiss WA
Oncogene; 2010 Mar; 29(9):1249-59. PubMed ID: 20101214
[TBL] [Abstract][Full Text] [Related]
46. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification.
Geerts D; Koster J; Albert D; Koomoa DL; Feith DJ; Pegg AE; Volckmann R; Caron H; Versteeg R; Bachmann AS
Int J Cancer; 2010 May; 126(9):2012-24. PubMed ID: 19960435
[TBL] [Abstract][Full Text] [Related]
47. Knockdown of astrocyte elevated gene-1 inhibits proliferation and enhancing chemo-sensitivity to cisplatin or doxorubicin in neuroblastoma cells.
Liu H; Song X; Liu C; Xie L; Wei L; Sun R
J Exp Clin Cancer Res; 2009 Feb; 28(1):19. PubMed ID: 19216799
[TBL] [Abstract][Full Text] [Related]
48. Genes proximal and distal to MYCN are highly expressed in human neuroblastoma as visualized by comparative expressed sequence hybridization.
Stock C; Bozsaky E; Watzinger F; Poetschger U; Orel L; Lion T; Kowalska A; Ambros PF
Am J Pathol; 2008 Jan; 172(1):203-14. PubMed ID: 18165268
[TBL] [Abstract][Full Text] [Related]
49. Molecular biology of neuroblastoma.
Castel V; Grau E; Noguera R; Martínez F
Clin Transl Oncol; 2007 Aug; 9(8):478-83. PubMed ID: 17720650
[TBL] [Abstract][Full Text] [Related]
50. Immunohistochemical evaluation of a novel clone of monoclonal anti-MYCN antibody B8.4B in neuroblastic tumours: a correlation with MYCN gene status.
Noguera R; Piqueras M; Subramaniam M; Cruz J; Cañete A; Bosch AL; Navarro S
Virchows Arch; 2006 Aug; 449(2):277-8. PubMed ID: 16685541
[No Abstract] [Full Text] [Related]
51. Prognostic factors including neoadjuvant chemotherapy in Mexican children with neuroblastoma.
Olaya-Vargas A; Rivera-Luna R; Cárdenas-Cardós R; Castellanos Toledo A; Pérez González OA; Robles Castro J; Calderón Elvir C
Clin Transl Oncol; 2005; 7(1):12-7. PubMed ID: 15890150
[TBL] [Abstract][Full Text] [Related]
52. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification.
Hansford LM; Thomas WD; Keating JM; Burkhart CA; Peaston AE; Norris MD; Haber M; Armati PJ; Weiss WA; Marshall GM
Proc Natl Acad Sci U S A; 2004 Aug; 101(34):12664-9. PubMed ID: 15314226
[TBL] [Abstract][Full Text] [Related]
53. Neuroblastoma: evolving therapies for a disease with many faces.
Goldsby RE; Matthay KK
Paediatr Drugs; 2004; 6(2):107-22. PubMed ID: 15035651
[TBL] [Abstract][Full Text] [Related]
54. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
[TBL] [Abstract][Full Text] [Related]
55. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
56. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
57. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
[TBL] [Abstract][Full Text] [Related]
58. Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group.
George RE; Variend S; Cullinane C; Cotterill SJ; McGuckin AG; Ellershaw C; Lunec J; Pearson AD;
Med Pediatr Oncol; 2001 Jan; 36(1):169-76. PubMed ID: 11464876
[TBL] [Abstract][Full Text] [Related]
59. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
